NTLA250117C25000
- 0.05
- -0.05-50.00%
Intellia Therapeutics Newsroom
Intellia Therapeutics' Strategic Reorganization and Promising Clinical Progress Justify Buy Rating
Express News | Intellia Therapeutics Inc : Jefferies Cuts Target Price to $86 From $128
Express News | Intellia Therapeutics Inc : Oppenheimer Cuts Target Price to $40 From $60
BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $50
Strategic Focus and Financial Resilience: Terence Flynn's Positive Outlook on Intellia Therapeutics
Barclays Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $55
Analysts' Top Healthcare Picks: Inozyme Pharma (INZY), Intellia Therapeutics (NTLA)
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $29 to $60
Intellia Therapeutics Price Target Lowered to $60 From $70 at Wells Fargo
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce
Peering Into Intellia Therapeutics's Recent Short Interest
Intellia Therapeutics Shares Are Trading Lower After the Company Announced a Strategic Reorganization to Prioritize Late-stage Programs NTLA-2002 and Nexiguran Ziclumeran.
Express News | Intellia Therapeutics Shares Are Trading Lower After the Company Announced a Strategic Reorganization to Prioritize Late-stage Programs NTLA-2002 and Nexiguran Ziclumeran
Why Is Intellia Therapeutics Stock Trading Lower On Friday?
Gene Editing Stocks Drop as Intellia Announces Layoffs
Intellia Therapeutics Price Target Lowered to $50 From $70 at BMO Capital
Intellia Therapeutics Is Maintained at Overweight by Wells Fargo
Express News | BMO Capital Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $50
Intellia Therapeutics Analyst Ratings
Express News | Intellia Therapeutics Inc : Wedbush Cuts Target Price to $10 From $14